Are plasma levels of axonal damage and neuronal degeneration makers altered in COVID-19 patients without major neurological manifestations?

NewsGuard 100/100 Score

Apart from respiratory symptoms, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19) pandemic, causes neurological symptoms, particularly in those with severe infection.

Study: Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes. Image Credit: Kateryna Kon/Shutterstock
Study: Transient Changes in the Plasma of Astrocytic and Neuronal Injury Biomarkers in COVID-19 Patients without Neurological Syndromes. Image Credit: Kateryna Kon/Shutterstock

The majority of individuals infected with SARS-CoV-2 remain asymptomatic or develop mild symptoms. However, the older population and those with comorbidities are susceptible to developing a severe infection and succumbing to multi-organ disorders.

Background

Neuropathological symptoms, such as headaches and dizziness, are commonly found in COVID-19 patients. In an insignificant number of patients, the SARS-CoV-2 virus was detected in the brain. Despite this, the viral load was found to be low in such patients. In addition, several studies demonstrated that cytokine-induced neuroinflammation was the main underlying mechanism associated with SARS-CoV-2-related encephalitis. Therefore, it is still not clear whether these neurological manifestations are associated with SARS-CoV-2 brain infections, severe infection, or are facilitated by the neuroinflammatory response.

Previous studies have pointed out several alterations in the levels of neuronal cerebrospinal (CSF) and glial cells (neuroglia). Also, changes in plasma biomarkers of COVID-19 patients with neurological symptoms were observed. For instance, changes in neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) levels were found in COVID-19 patients with neurological manifestations. These studies documented evidence to support plasma NfL as a marker for neuroaxonal damage and GFAP as a marker for astrocytic activation/injury. Total tau (T-tau) protein has been considered to be another marker for axonal damage and neuronal degeneration in COVID-19 patients.

Very few studies have found altered levels of plasma NfL among COVID-19 patients (adults) with mild symptoms and those who were asymptomatic. However, no changes in NfL levels were found in children with mild/moderate COVID-19 or asymptomatic.

About the study

A recent International Journal of Molecular Sciences study evaluated whether plasma levels of NfL, T-tau, and GFAP changed in SARS-CoV-2 infected patients with or without major neurological manifestations. In addition, the authors studied if the changes in plasma levels got restored after patients recovered from the infection. Forty-five plasma samples from COVID-19 patients who required hospitalization were obtained. This study cohort included 18 females and 27 males whose mean age was 64.

Study findings

Typically, manifestations of neurological symptoms resulting from systemic diseases have been associated with a high risk of morbidity and mortality. Therefore, it is important to mitigate the adverse impact of COVID-19 on the nervous system. 

Herein, the authors demonstrated a significant increase in plasma concentrations of GFAP, T-tau, and NfL, in COVID-19 patients associated with non-substantial neurological manifestation, compared with controls. This finding is in line with previous studies that reported elevated baseline serum NfL levels in COVID-19 patients without significant neurological symptoms, irrespective of disease severity. Interestingly, the levels of NfL increased during repeated measurements in non-survivors; however, this level remained stable in patients who recovered from COVID-19.

No changes in CNS damage biomarkers were observed between subgroups, i.e., those with severe COVID-19 and post-COVID patients with insignificant neurological manifestations. Previous studies indicated an increase in plasma T-tau in convalescent COVID-19 patients at follow-up, and the levels were not dependent on initial disease severity. These levels were also not associated with impaired immune responses.

A weak correlation was observed between increased CNS damage biomarkers and certain hematological parameters, such as inflammatory-associated troponin and D-dimer. T-tau was negatively correlated with C-reactive protein, and no connection was found with the pro-inflammatory cytokine IL-6.

Notably, plasma levels of GFAP, NfL, and T-tau were normalized after two months of recovery from COVID-19, with or without minor post-acute neurological sequelae. Consistent with this finding, another study revealed that after six months of SARS-CoV-2 infection, NfL and GFAP levels, which were elevated during the acute phase of the disease, returned to normal levels.

Conclusions

This study has some limitations, including the small sample size and the absence of samples from patients with major neurological symptoms. In addition, the samples were obtained during the first COVID-19 wave, when neurological manifestation could have been underestimated. Despite the limitations, the current study demonstrated that elevated plasma NfL, GFAP, and T-tau levels in COVID-19 patients during the acute phase of infection, indicate a high risk of CNS manifestation. Nevertheless, changes in the above biomarker levels also occur in COVID-19 patients without delayed neurological manifestation.

Journal reference:
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2023, February 03). Are plasma levels of axonal damage and neuronal degeneration makers altered in COVID-19 patients without major neurological manifestations?. News-Medical. Retrieved on June 14, 2024 from https://www.news-medical.net/news/20230203/Are-plasma-levels-of-axonal-damage-and-neuronal-degeneration-makers-altered-in-COVID-19-patients-without-major-neurological-manifestations.aspx.

  • MLA

    Bose, Priyom. "Are plasma levels of axonal damage and neuronal degeneration makers altered in COVID-19 patients without major neurological manifestations?". News-Medical. 14 June 2024. <https://www.news-medical.net/news/20230203/Are-plasma-levels-of-axonal-damage-and-neuronal-degeneration-makers-altered-in-COVID-19-patients-without-major-neurological-manifestations.aspx>.

  • Chicago

    Bose, Priyom. "Are plasma levels of axonal damage and neuronal degeneration makers altered in COVID-19 patients without major neurological manifestations?". News-Medical. https://www.news-medical.net/news/20230203/Are-plasma-levels-of-axonal-damage-and-neuronal-degeneration-makers-altered-in-COVID-19-patients-without-major-neurological-manifestations.aspx. (accessed June 14, 2024).

  • Harvard

    Bose, Priyom. 2023. Are plasma levels of axonal damage and neuronal degeneration makers altered in COVID-19 patients without major neurological manifestations?. News-Medical, viewed 14 June 2024, https://www.news-medical.net/news/20230203/Are-plasma-levels-of-axonal-damage-and-neuronal-degeneration-makers-altered-in-COVID-19-patients-without-major-neurological-manifestations.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vitamin D receptor polymorphism found to influence COVID-19 severity